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Abstract
Purpose To validate two health-related quality of life
(HRQOL) measures, the PedsQL Generic Core and Cancer
Module adolescent forms (13–18 years), after modification
for 16–25-year-old adolescents and young adults (AYA)
with cancer or a blood disorder.
Methods AYA patients and nominated proxies were
recruited from three Sydney hospitals. Modified forms
were administered by telephone or in clinics/wards. Anal-
yses included correlations, factor analysis, and analysis of
variance of known-groups (defined by the Memorial
Symptom Assessment Scale).
Results Eighty-eight patients and 79 proxies completed
questionnaires. Factor structures consistent with those of
the unmodified forms confirmed construct validity. Cron-
bach’s alpha ranged 0.81–0.98. Inter-scale correlations
were as hypothesized, confirming discriminant validity.
Statistically significant differences between groups with
mild, moderate, and severe symptoms (P \ 0.05) con-
firmed clinical validity.
Conclusion These modified forms provide reliable and
valid measures of HRQOL in AYA with cancer or a blood
disorder, suitable for clinical trials, research, and practice.
Keywords Quality of life  Adolescents  Validation
studies  Cancer  Blood disorder  Proxy
Introduction
Disease and treatment affect many aspects of the quality of
people’s lives—not only physical aspects but also social
and emotional aspects. The diseases themselves can cause
symptoms such as fatigue and pain. Common treatments
such as chemotherapy, radiotherapy, and surgery, whether
palliative or curative, can have deleterious side-effects as
well as beneficial effects [1, 2]. The importance of these
issues, not only to patients but also to their families, carers,
and clinicians, has led to the development of instruments
designed to measure the impact of a range of diseases and
treatments by self-report. These instruments are commonly
called health-related quality of life (HRQOL) measures.
There are a large number and wide array of HRQOL
instruments, and a comprehensive methodology for testing
their reliability, validity, responsiveness, and interpret-
ability [3].
Adolescents and young adults (AYA) with cancer and
blood disorders are an obvious case for HRQOL assessment
because they lack an appropriate model of care [4] and the
range of implications for them is very different from that for
adults and younger children. Furthermore, AYA percentage
improvement in survival lags behind all other age-groups
[1, 5–7]. AYA may experience interruptions in physical
growth, pubertal development, psychosocial and cognitive
development [3, 7], and to their education, employment,
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and independence [1, 7, 8]. In relation to cancer, there are
numerous instruments to measure HRQOL, such as the
modular approaches of both the EORTC [9] and the FACT-
G [3, 10], but few for those with blood disorders. Most
HRQOL instruments are designed for adults and some for
paediatric patients. Adult questionnaires are inappropriate
for paediatric patients because of their reading and com-
prehension levels, whereas AYA, being between childhood
and adulthood, have different developmental needs, issues,
and concerns [1, 7]. Little is known about the patient’s sat-
isfaction, preferences for services, impact of illness, and
HRQOL as few validated AYA instruments are available
that address their developmental needs.
Common treatments for blood disorders may include
chelation and blood transfusions. The chronic and serious
nature of these diseases and treatments further heightens
the special needs of AYA [1, 7, 11, 12]. Despite this, too
few are included in clinical trials [1, 7, 13]. With increasing
international recognition of the inadequacy of AYA care,
the European Journal of Cancer dedicated the 18th issue of
the 39th volume 2003 to this age-group.
The Pediatric Quality of Life Inventory (PedsQL) is a
suite of instruments designed to measure HRQOL in chil-
dren, and in adolescents aged 13–18 years [14–16] using a
30-day recall period. The approach is modular, with generic
core scales complemented by disease-specific modules,
such as the PedsQL Cancer Module. The validity and reli-
ability of the PedsQL has been demonstrated in various
paediatric populations e.g. cancer [17], diabetes [18], and
heart disease [19]. There are parallel child self-report and
parent proxy-report formats, and age-specific forms differ-
ing in developmentally appropriate language for ages
2–4 years (toddler, proxy-report only), 5–7 years (young
child), 8–12 years (child), and 13–18 years (adolescent)
[14–16, 20].
The aim of this study was to modify the existing ado-
lescent forms of the PedsQL 4.0 Generic Core Scales and
PedsQL 3.0 Cancer Module appropriate to AYA aged
16–25 years with cancer or a blood disorder, and evaluate
the reliability and validity of these modified forms.
Methods
Participants, recruitment and consent
AYA inclusion criteria were: aged 16–32 years old and
diagnosed with cancer or a blood disorder at least three
months prior to recruitment (to allow participants time to
adjust to their diagnosis and treatment). AYA exclusion
criteria were: inability to read and write English; co-mor-
bidity; major developmental disorder; receiving end-of-life
care; recently diagnosed; or involved in a concurrent ‘‘late
effects’’ study. Proxies were also recruited; the only proxy
exclusion criterion was lack of English literacy. Recruit-
ment occurred from 1st July 2003 to 31st May 2004 via
three Sydney hospitals: Sydney Children’s Hospital, Prince
of Wales Hospital, and Royal Hospital for Women. Eligi-
ble AYA participants were identified from databases or
patient records by a member of the medical team in liaison
with the hospital research scientist, database managers, or
clinical nurse consultant. Permission was sought from the
treating clinician to approach eligible patients. Most AYA
participants were recruited by phone after receiving an
introductory letter from their treating clinician; some were
recruited on wards or at out-patient clinics. All participants
provided informed, written consent, and could withdraw at
any time. Permission was gained from AYA participants to
approach their nominated proxy/caregiver. If the nomi-
nated proxy was absent, and the young adult patient agreed,
the proxy was contacted and recruited, usually by phone
and post.
The study was approved by the Scientific Review Com-
mittees of the South Eastern Sydney Area Health Service
and Royal Hospital for Women, and the University of
Technology Sydney Human Ethics Research Committee.
The PedsQL instruments
The PedsQL 4.0 Generic Core Scales and PedsQL 3.0
Cancer Module adolescent forms were used after minor
modification in wording for AYA (described below). The
generic core scales contain 23 items grouped into four
scales—Physical Health Summary Score (eight items),
Emotional (five items), Social (five items), and School (five
items)—plus composite scales for a Total Scale Score (23
items) and a Psychosocial Health Summary Score (the sum
of Emotional, Social, and Study/Work functioning, 15
items). The cancer module contains 27 items, grouped into
eight scales—Pain and Hurt (two items); Nausea (five
items); Procedural Anxiety (three items); Treatment Anxi-
ety (three items); Worry (three items); Cognitive Problems
(five items); Perceived Physical Appearance (three items);
and Communication (three items) [14–20].
Modifications to PedsQL instruments for AYA
The existing adolescent report (ages 13–18 years) and
associated parent report of the Generic Core Scales and the
Cancer Module were used as the basis for the corre-
sponding AYA forms. The modifications were based on
feedback from two focus groups conducted by the first
author (JE) in Auckland, New Zealand, in 1999; one group
comprised a dozen AYA patients and family members, the
other comprised eight health and allied health profession-
als, including nurses, doctors, and social workers who
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cared for AYA patients. The instruments’ principal
developer and copyright holder, Professor James Varni,
approved the proposed wording modifications (Table 1).
The most substantial change was to the school functioning
scale of the Generic Core Scales, in which references to
school were rephrased to reflect this mildly older age
group’s engagement in combinations of study and work.
The Generic Core Scales and the Cancer Module have the
same item stem and response options, and are as in the
adolescent forms. The item stem in the AYA forms asks: ‘‘In
the past one month, how much of a problem has this been for
you’’. In the corresponding proxy forms, it asks: ‘‘In the past
month, how much of a problem has your charge/child had
with…’’ and the item descriptions are written in the third
person rather than the first person. The response options are
the same for both AYA and proxy forms: 0 = never;
1 = almost never; 2 = sometimes; 3 = often; 4 = almost
always.
Memorial symptom assessment scale (MSAS)
We tested the clinical validity of the HRQOL measures [21]
against the memorial symptom assessment scale (MSAS)
[22, 23], an external criterion, rather than use the more
general divisions used by Varni et al. in earlier work (on-
treatment in the past 12 months versus off-treatment for
more than 12 months [14, 20] and chronically ill versus
acutely ill and healthy populations of young people [15]).
The MSAS [22, 23] is a previously validated 30-item
patient-rated instrument which provides multidimensional
information about the symptoms experienced by people with
cancer in the past week. It was used to categorise AYA
participants into three known groups based on the tertiles of
the sample’s MSAS-PHYS scores: Mild (0–0.19), Moderate
(0.20–0.99), and Severe (1.0–4.0) Symptoms.
Data collection
AYA participants were given or posted a booklet con-
taining a set of questionnaires, in this order: PedsQL
Generic Core Scales; PedsQL Cancer Module; AYA
satisfaction survey; preferences survey; MSAS (for AYA
only); global impact survey; and questions about their
current disease, treatment, and socio-demographics. Each
proxy participant was nominated by the AYA patient and
were given or posted a booklet containing parallel versions
of the AYA questionnaires. All participants were encour-
aged to follow the PedsQL administration guidelines [14].
Instrument scoring
The PedsQL scales were scored according to Varni’s
standard algorithm [14]. Each domain score was the
unweighted sum of the item scores, linearly transformed to
a 0–100 scale range on which a higher score represented
better quality of life. If less than 50% of the items in a scale
were missing, the missing item values were imputed as the
mean of the completed items within that scale [24];
otherwise the scale score was recorded as missing [3, 25,
26]. This method is considered the least biassed procedure
for missing data, although it may artificially reduce vari-
ability [15, 24]. The MSAS scoring, including missing
values, was as recommended elsewhere [22, 23].
Validation analyses
Several aspects of construct validity were investigated.
Confirmatory factor analysis [3, 14] was used to determine
whether the modified items correlated within domains in
the same way as reported by Varni et al. [14]. Internal
consistency reliability was summarised with Cronbach’s
alpha coefficient [14, 27, 28]. Correlation matrices (Pear-
son’s and Kendall’s Tau b correlation coefficients) were
used to examine the degree and pattern of correlation
among multi-item scales. In this context, correlations in the
range 0.1–0.29 were considered a small effect; those in the
range 0.3–0.49 were considered moderate and those greater
than 0.5 were considered large [29]. Known-groups anal-
ysis was used to test the clinical validity of the new AYA
forms [21]. The MSAS [22, 23] provided an external cri-
terion to categorise patients into three groups identified by
AYA scores on the MSAS-PHYS scale where symptom
Table 1 Modifications to the existing adolescent report and associated parent report of the PedsQL Generic Core Scales (GC) and PedsQL
Cancer Module (CM) to create the adolescent and young adult (AYA) self-report and associated proxy-report forms
Adolescent
form
Adolescent and young adult form Instrument, domain and item numbers
Ages 13–18 Ages 16–24 (incl.) GC and CM—instrument front page
Teen or teens Young person or young people or young adult(s) GC and CM—instrument front page; social functioning: items 1–5
School Study/work or study GC, work/study functioning, items 4 and 5; GC, cognitive problems, item 3
Class Class/at work GC, work/study functioning, item 1
Schoolwork Study/work duties GC, work/study functioning, item 3
Child Child/charge GC and CM (proxy-report only)
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severity cut-off points were determined as: Mild (MSAS-
PHYS = 0–0.19), Moderate (MSAS-PHYS = 0.20–0.99),
Severe Symptom (MSAS-PHYS = 1–max). The mean
HRQOL scores of these groups were compared to see
whether they conformed to patterns predicted by clinical
knowledge of this external criterion. Thus patients who
reported severe symptom experience were expected to
have worse HRQOL in all domains than those who
reported moderate symptom experience, and this inter-
mediate group was expected to have worse HRQOL in all
domains than those who reported mild symptom experi-
ence. These hypotheses were tested with ANOVA for
the Generic Core and pair-wise P-values were calcu-
lated using Tukey’s HSD post-hoc test. However, because
distributions for some of the scores from the Cancer
Module did not meet normality requirements, the Krus-
kal–Wallis (K–W) non-parametric test was used to test
differences between symptom groups and the Mann–
Whitney U-test was used to determine significance
between pairs of groups within domains.
The degree of agreement between AYA self-report and
proxy report was tested with intraclass correlations, and the
degree of proxy bias was assessed by testing the mean
difference between self-report and proxy-report scores with
a Mann–Whitney U-test. All analyses were conducted with
the Statistical Package for Social Scientists (SPSS) for
Windows and all tests of significance were two-sided at the
95% confidence level.
Table 2 Clinical and socio-
demographic profile of the
sample (%)
a All items are reported by the
AYA and their nominated Proxy
b 17% of AYA had a
combination of 2 or 3 different
types of treatment in the past
month, e.g., surgery,
chemotherapy and a transfusion.
Hence Treatments add to [
100% due to duplications
c Missing data: Proxy age 10%,
Proxy marital status 10%,
Educational status: AYA 2%
and proxy 10%
Characteristicsa Adolescent and young
adults (n = 88)
Nominated
proxies (n = 79)
Illness Cancer 74
Blood disorder 26













Age brackets—AYA 16–19 years 54
20–25 years 46





Ethnic group European descent 77 81
Other 23 19
Gender Female 58 76





Educational statusc 9th Grade or less 3 10
9th–12th Grade 49 21
High school certificate 17 16
Tertiary cert course 15 23
Graduate or prof degree 14 21
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Results
Eighty-eight AYA participants and 79 nominated proxy/
caregivers were recruited. Ten people declined participa-
tion: two patient-proxy dyads, three AYA patients (who
declined but were happy for their proxies to participate),
and a further three proxies. Some AYA did not wish to
nominate a proxy. Most AYA participants were recruited
by phone and completed their questionnaires at home
(n = 68, 78%). The remainder were recruited at out-patient
clinics (n = 16) or as hospital in-patients (n = 4), and
completed their questionnaires in a clinic or ward. Most
proxies completed their questionnaires at home, 86% were
parents and 7% were partners of AYA. Of the 167 com-
pleted questionnaires, few items were missed: the
percentage of missed items for the generic instrument for
AYA and proxy-reports was 0% and 0.1%, respectively.
The response rate for the Cancer Module was similar to
that for the Generic Core.
Table 2 shows the clinical and demographic character-
istics of the AYA and their proxies. Cancer diagnoses
included leukaemia, Hodgkin’s lymphoma, non-Hodgkin’s
lymphoma, Ewing’s sarcoma, Wilm’s tumour, neuroblas-
toma, carcinoma, and osteosarcoma. Of the 23 young
Table 3 Adolescent and young adult (AYA) self-report of their quality of life using the AYA modified PedsQL Generic Core Scales and Cancer
Modulea: mean (SD) and Cronbach’s alphab (a) for the sample as a whole, and ceiling and floor effectsc for each of the three known groupsd
Total Score 23 76 (19) .95 0 11 0 0 0 0
Physical Health 8 75 (25) .93 0 41 0 10
Psychosocial Health 15 76 (17) .92 0 14 0 0 0 0
Emotional
Functioning 5 73 (20) .86 0 32 0 5 0 0
Social Functioning 5 88 (15) .81 0 68 0 31
Study/Work 
Functioning 5 69 (26) .88 0 27 0 0 0 0
     Cancer Module
Pain & Hurt 2 75 (24) .75 0 60 0 21
Nausea 5 84 (21) .89 0 62 0 31
Procedural Anxiety 3 80 (29) .85 0 70 5 39 17 17
Treatment Anxiety 3 80 (28) .83 0 70 8 33 5
Worry 3 69 (23) .76 0 24 0 0 0 8
Cognitive Problems 5 73 (25) .90 0 46 0 13 7
Perceived
Appearance 3 73 (25) .77 0 43 0 18 7



















b %Floor %Ceiling %Floor %Ceiling %Floor %Ceiling
a The PedsQL Generic Core Scales and the PedsQL Cancer Module has a 1-month recall interval
b Internal consistency reliability coefficient, Cronbach’s alpha (a)
c % Floor and % Ceiling are the percentage of scores at the extreme values of the scale range
d Known groups determined by AYA scores on the MSAS-PHYS: Mild symptoms (MSAS-PHYS = 0–0.19), Moderate (MSAS-PHYS = 0.20–
0.99), and Severe Symptom (MSAS-PHYS = 1–max)
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adults with a blood disorder, 13 had thalassemia and ten
had other blood disorders such as sickle cell anemia, Von
Willebrand’s disease, anemia, and haemophilia. The AYA
age distribution was bimodal (at 17 and 22 years); 54%
were 16–19 years and 46% were 20–25 years with two
outliers (26, 32 years). There were no more than 10%
missing data, and 17% of AYA had a combination of two
or three different types of treatment in the past month, e.g.
surgery, chemotherapy, and a transfusion. Hence treat-
ments add to more than 100% because of duplication.
Of the 88 AYA participants, 37 reported mild to no
symptoms, 39 reported moderate symptoms, and 12
Table 4 Proxy-report of adolescent and young adult (AYA) quality of life using the AYA modified PedsQL Generic Core Scales and PedsQL









Generic Core No. of items
Mean
(SD) %Floor %Ceiling %Floor %Ceiling %Floor %Ceiling
Total Score 23 74 (21) .96 0 23 0 3 0 0
Physical Health 8 75 (26) .93 0 37 0 15
Psychosocial
Health 15 74 (21) .94 0 29 0 3 0 0
Emotional
Functioning 5 69 (26) .91 0 40 0 12
Social Functioning 5 85 (18) .85 0 60 0 41 0
Study/Work
Functioning 5 69 (27) .89 0 40 0 12
      Cancer Module
Pain & Hurt 2 75 (25) .85 0 54 0 29 0
Nausea 5 83 (25) .95 0 77 0 47 10 0
Procedural Anxiety 3 81 (28) .98 0 74 6 53 10 10
Treatment Anxiety 3 77 (27) .94 3 66 3 29 0
Worry 3 68 (27) .91 0 34 0 18 10 0
Cognitive









Appearance 3 74 (26) .83 0 49 3 24 10 10
Communication 3 77 (26) .89 0 51 3 35 10 30
b
a The PedsQL Generic Core Scales and the PedsQL Cancer Module has a 1-month recall interval
b Internal consistency reliability coefficient, Cronbach’s alpha (a)
c % Floor and % Ceiling are the percentage of scores at the extreme values of the scale range
d Known groups determined by AYA scores on the MSAS-PHYS: Mild symptoms (MSAS-PHYS = 0–0.19), Moderate (MSAS-PHYS = 0.20–
0.99), and Severe Symptom (MSAS-PHYS = 1–max)
e Each proxy is as nominated by the AYA patient
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Table 5 Adolescent and young adult (AYA) self-report by Symptom Severity Group using the AYA modified PedsQL Generic Core Scales and
Cancer Module domain scores (n = 88)
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reported severe symptoms. Two-thirds (60/88) of the AYA
patients were off-treatment (Table 2), and of these, 45%
(27/60) reported moderate to severe symptoms. A quarter
of the people with severe symptoms were off-treatment at
recruitment.
Table 3 (self-report) and Table 4 (proxy-report) show
the means, standard deviations (SD), and internal consis-
tency Cronbach’s alpha (a), coefficients of the AYA
modified Generic Core Scales and Cancer Module scores
for the whole sample, and the percentage of scores at the
ends of the scale range (floor and ceiling effects) for the
three symptom-severity groups. Minimal missing responses
on items of the AYA version of the Generic Core Scales
and Cancer Module suggested that participants were will-
ing and able to provide good quality data regarding AYA
HRQOL. Cronbach’s alpha values for scales of the Generic
Core ranged from 0.81–0.95 (AYA) and 0.85–0.96 (proxy),
and for the modified Cancer Module they were 0.75–0.90
(AYA) and 0.83–0.98 (Proxy).
Table 5 (self-report) and Table 6 (proxy-report) show
that the gradient of the mean HRQOL scores across the
symptom-severity groupings was as expected. Most pair-
wise comparisons were statistically significant (readily seen
in the column marked ‘‘Groups’’), demonstrating the ability
of the scales to distinguish between these symptom groups.
Factor structures were consistent with those reported
previously for the Generic Core (Table 7) and Cancer
Module (Table 8), for both self-report and proxy-report.
Proportions of variance accounted for in self-report and
proxy-report were: Generic Core 74% and 75% explained
by a five-factor solution; and Cancer Module 76% and 84%
by a six-factor solution. Item factor loadings from Varni’s
original sample [15] are presented in Table 7 for compar-
ison; these relate to version 4.0 administered in a sample
aged 2–18 years. In our analyses, more of the variance was
accounted for (74% patient and 75% proxy) than in Varni’s
original study in children (52% and 62%, respectively)
[16].
Table 9 shows the correlations between the AYA
modified Generic Core Scales and Cancer Module for AYA
versus AYA (above the leading diagonal) and proxy versus
proxy (below the diagonal), with AYA-proxy concordance
shown in bold on the leading diagonal. Correlations among
the scales of the Generic Core and the Cancer Module were
generally in the moderate to large size range for both self-
report (i.e. AYA vs. AYA Generic Core: 0.53–0.95; Cancer
Module: 0.23–0.65) and proxy-report (i.e. Proxy vs. proxy
0.54–0.95 and 0.30–0.75).
The self/proxy correlations were as expected, generally
in the medium to large size range (r = 0.56–0.85 Generic
Core and 0.36–0.67 Cancer Module). There was little
systematic bias between AYA self-report and proxy
(Fig. 1a, Generic Core Scales; Fig. 1b, Cancer Module).
The only statistically significant difference was for the
social functioning scale (P = 0.037), with proxies under-
estimating AYA HRQOL. Proxies also underestimated
emotional function (P = 0.08) and psychosocial health
summary score (P = 0.10).
Table 5 continued
a GC scales, analysed using One-way ANOVA, pair-wise P-values calculated by Tukey’s HSD Post Hoc Test
b Known groups, ‘‘Mild’’, ‘‘Moderate’’ and ‘‘Severe’’ were identified by AYA scores on the MSAS-PHYS scale
c The ‘‘Groups’’ column shows the level of significance between pairs of symptom groups e.g., for Emotional Functioning a weak difference
between Moderate and Severe symptom groups, 2 and 3 is shown as (P = 0.053), while Cognitive Problems shows no significant
difference between groups 2 and 3 (P = 0.163)
d Significance levels: * indicates P-values B 0.05; ** indicates P-values B 0.01; and *** indicates P-values B 0.001
e CM scales did not meet normality requirements so non-parametric analyses were conducted
f The Mann-Whitney U-test was used to determine significance between pairs of groups within domains of CM
g The Kruskal-Wallis (K-W) non-parametric Test, used to decide significance between CM symptom groups
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Table 6 Proxy-report by Symptom Severity Group using the AYA modified PedsQL Generic Core Scales and Cancer Module domain scores
(n = 79)
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Table 6 continued
a GC scales, analysed using One-way ANOVA, pair-wise P-values calculated by Tukey’s HSD Post Hoc Test
b Known groups, ‘‘Mild’’, ‘‘Moderate’’ and ‘‘Severe’’ were identified by AYA scores on the MSAS-PHYS scale
c The ‘‘Groups’’ column shows the level of significance between pairs of symptom groups e.g., Proxies reported significant differences between
symptom groups for Emotional Functioning at 5% level i.e., ‘‘1 2 3’’, and no difference between Mild and Moderate symptom groups for Social
functioning i.e., P = 0.744
d Significance levels: * indicates P-values B 0.05; ** indicates P-values B 0.01; and *** indicates P-values B 0.001
e CM scales did not meet normality requirements so non-parametric analyses were conducted
f The Mann-Whitney U-test was used to determine significance between pairs of groups within domains of CM
g The Kruskal-Wallis (K-W) non-parametric Test, used to decide significance between CM symptom groups
Table 7 Factor structurea of the AYA modified PedsQL Generic Core Scales for the self- and proxy-report from the Ewing sample and from
Varni’s original validation sampleb
administered in a sample aged 2–18 years and parent-proxies
a Item factor loadings from Principal Components Analysis with Varimax Rotation and an Eigenvalue cut-off at 1.0
b Ewing sample (as reported in this paper) is labelled E1–5; Varni’s sample is labelled V1–5 (as reported in Varni (2001), where version 4.0 was
Generic Core 
Self-Report n = 88 Proxy-Report  n = 79
1 2 3 4 5 1 2 3 4 5
     Physical Functioning E1 V2 E2 V1 E3 V5 E4 V3 E5 V4 E1 V1 E2 V3 E3 V2 E4 V5 V4
Hard to walk more than one block 0.84 -0.72 0.09 -0.05 0.16 0.05 0.13 0.00 0.24 0.12 0.90 0.83 0.13 0.04 0.09 -0.11 -0.03 -0.02 0.02
Hard to run 0.76 -0.77 -0.08 0.10 0.19 0.12 0.12 -0.06 0.46 0.05 0.89 0.84 0.21 0.07 -0.08 -0.18 0.03 -0.01 0.04
Hard to do sports activity/exercises 0.76 -0.78 0.05 0.09 0.23 0.06 0.12 0.01 0.39 0.00 0.88 0.80 0.11 0.10 -0.01 -0.09 0.09 0.01 0.06
Hard to lift something heavy 0.69 -0.46 0.22 0.14 0.16 0.05 0.29 0.06 0.27 0.16 0.81 0.75 0.23 0.10 0.15 0.03 0.18 -0.08 0.04
Hard to take a bath/shower unaided 0.78 -0.57 0.27 -0.06 -0.12 -0.24 -0.04 0.01 -0.02 -0.14 0.63 0.72 0.02 -0.11 0.48 0.22 -0.14 -0.02 -0.08
 Hard to do chores around house 0.88 -0.65 0.08 -0.04 0.11 -0.21 0.11 0.01 -0.05 -0.11 0.70 0.74 0.19 -0.02 0.26 0.19 0.25 -0.02 -0.07
Hurt or ache 0.65 -0.25 0.34 0.22 0.19 0.03 0.12 0.05 0.19 0.20 0.59 0.31 0.35 0.33 0.30 -0.15 0.15 -0.02 0.29
 Low energy 0.68 -0.26 0.38 0.39 0.35 -0.03 0.10 0.03 -0.08 0.14 0.57 0.27 0.54 0.37 0.32 -0.03 0.06 -0.04 0.30
     Emotional Functioning
Feel afraid or scared 0.19 -0.03 0.76 0.78 0.08 0.05 0.18 0.11 0.10 -0.18 0.17 0.04 0.82 0.72 0.12 0.00 0.29 0.04 -0.07
Feel sad or blue 0.21 0.10 0.68 0.78 0.11 -0.02 0.17 0.07 0.52 0.01 0.25 -0.02 0.80 0.77 0.35 0.05 0.15 0.08 -0.02
Feel angry 0.17 0.01 0.52 0.66 0.24 -0.11 -0.03 -0.04 0.61 -0.02 0.11 -0.04 0.72 0.66 0.38 0.09 0.07 0.10 -0.03
Trouble sleeping 0.30 -0.13 0.74 0.37 0.18 -0.18 0.08 0.05 -0.08 0.13 0.28 0.04 0.71 0.54 0.18 0.08 0.24 -0.01 0.16
Worry about what will happen 0.09 0.00 0.82 0.71 0.16 0.02 0.21 -0.07 0.14 0.04 0.24 -0.03 0.83 0.78 0.07 0.04 0.26 -0.02 -0.05
     Social Functioning
 Trouble getting along with peers -0.02 0.04 0.32 0.01 0.21 -0.18 0.60 0.68 0.30 -0.08 0.13 0.04 0.29 0.09 0.33 0.25 0.62 0.60 -0.16
 Other youth not wanting to be friends 0.13 0.02 0.15 -0.04 0.15 -0.05 0.84 0.81 0.05 -0.11 0.05 -0.04 0.38 0.06 0.07 0.02 0.82 0.84 -0.02
Teased 0.19 0.10 0.10 0.09 0.08 -0.01 0.83 0.75 0.06 0.05 0.15 -0.06 0.09 0.10 0.18 -0.10 0.83 0.81 0.08
Unable to do things peers do 0.60 -0.31 0.05 0.07 0.10 0.17 0.33 0.42 0.59 0.18 0.72 0.48 0.20 -0.08 0.36 0.02 0.28 0.41 0.13
Hard  to keep up with peers 0.45 -0.35 0.12 -0.03 0.17 0.21 0.33 0.42 0.67 0.24 0.71 0.55 0.23 -0.13 0.32 0.15 0.26 0.37 0.12
     Study/Work Functioning
Hard to concentrate class/at work 0.28 -0.06 0.16 0.12 0.83 -0.71 0.19 0.08 0.18 0.04 0.26 0.03 0.31 0.09 0.76 0.81 0.29 0.06 0.01
Forget things 0.04 0.00 0.19 0.21 0.86 -0.52 0.21 0.09 0.05 0.14 0.10 0.03 0.31 0.13 0.68 0.73 0.38 -0.03 0.08
Trouble keeping up with study/work 0.50 -0.12 0.11 -0.05 0.68 -0.68 0.07 0.14 0.22 0.20 0.26 0.02 0.42 0.04 0.72 0.77 0.26 0.05 0.15
Miss class/work - not feeling well 0.62 0.00 0.35 0.00 0.53 -0.14 0.10 -0.05 0.11 0.80 0.49 -0.04 0.53 -0.04 0.45 0.11 0.14 -0.05 0.90
Miss class/work - Dr or hospital appt. 0.66 0.06 0.30 -0.03 0.37 -0.07 -0.02 -0.01 0.17 0.85 0.60 -0.03 0.41 -0.02 0.41 0.07 -0.05 0.07 0.86
%  of Total Variance 47% 10% 7% 6% 4% 51% 13% 6% 5%
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Discussion
This study presents the measurement properties for new
adolescent and young adult (AYA) forms of the PedsQL
Generic Core Scales and PedsQL Cancer Module [14],
with patient self-report and parallel versions for their
nominated proxy in the context of cancer or a blood dis-
order. Our results support the reliability and validity of the
AYA forms, both in self report and proxy versions, with
reasonable agreement and correlation between AYA and
proxies. Factor structures generally consistent with those of
the adolescent forms confirmed construct validity. Cron-
bach’s alpha were all greater than 0.81, confirming internal
constancy reliability. Inter-scale correlations were as
hypothesized, confirming discriminant validity. Statisti-
cally significant differences between groups with mild,
moderate and severe symptoms confirmed clinical validity.
The scales of these instruments demonstrated minimal
ceiling effects and no floor effects in this patient group.
These results demonstrate that these new AYA forms are
suitable for clinical research.
We have demonstrated that the new AYA forms of the
PedQL Generic Core Scales and Cancer Module can
differentiate the expected HRQOL gradient across mild,
moderate, and severe symptom groups. As hypothesised,
HRQOL was inversely related to symptom level, consis-
tent with the conceptualisations of disease-specific
symptoms as causal indicators of HRQOL [3, pp 46, 66].
Our results corroborate Varni et al. for the acute version
self-report used in children on-treatment for more than
12 months versus healthy children, where the Generic
Core Scales showed significant differences across all
Table 8 Factor structurea of the AYA modified PedsQL Cancer Moduleb for self-report and proxy-report
Adolescents & Young Adults  Proxy Cancer Modul
Pain & Hurt
e 
1 2 3 4 5 6  1 2 3 4 5 6 
      
Aches in joints and/or muscles .143 .314 -.043 .757 -.025 -.022  -.174 .652 .108 .422 .160 .057 
Having a lot of pain .201 .484 .022 .671 -.010 .047  .049 .711 .140 .390 .232 .232 
Nausea              
Become nauseated during medical treatments .140 .755 -.014 .280 .283 -.131  .431 .821 .166 .109 .075 -.080 
Food not tasting very good .058 .825 .180 .227 .065 .059  .220 .809 .341 .019 .072 .029 
Become nauseated while thinking about medical treatments .199 .602 .243 .231 .447 -.078  .586 .653 .121 .252 .075 .117 
Feeling too nauseous to eat .287 .710 .087 .306 .088 .082  .366 .788 .204 .090 .187 .047 
Some foods and smells cause nausea .333 .726 .046 -.086 .071 -.005  .258 .841 .212 .077 -.036 .132 
Procedural Anxiety          
Problems with Needle Sticks (injections, blood tests, IV) Hurt .227 .175 .161 .148 .807 .100  .847 .284 .149 .140 .067 .141 
Get anxious about Blood Tests .058 .294 .506 -.116 .658 .205  .880 .129 .207 .149 .131 .176 
Get anxious about Needle Sticks (i.e. injections, BT and IV's) .155 .206 .431 .030 .762 .077  .880 .249 .191 .124 .075 .133 
Treatment Anxiety              
Get anxious while waiting to see the Doctor .273 .007 .841 .095 .195 .010  .672 .157 .119 .500 .271 .136 
Get anxious about going to the doctor .250 -.008 .828 .007 .306 .033  .707 .134 .147 .469 .289 .062 
Get anxious about going to the hospital .305 .036 .702 .215 .410 .034  .684 .317 .232 .409 .204 .077 
Worry              
Worry about side effects from the medical treatments -.086 .454 .207 .557 .255 .274  .454 .360 .070 .653 .139 .162 
Worry about whether the medical treatments are working .109 .198 .534 .547 .114 .173  .344 .283 .200 .771 .093 .117 
Worry that the cancer will reoccur -.061 .246 .754 -.028 .035 .276  .383 .099 .225 .741 -.015 .087 
Cognitive Problems              
Difficulty figuring out what to do when something is bothersome .592 .209 .319 .406 .107 .054  .269 .235 .593 .269 .332 .369 
Trouble solving maths problems .791 .149 .123 -.033 .202 .067  .123 .136 .822 .108 .212 .152 
Trouble writing study papers or reports .834 .219 .192 .044 -.021 .087  .139 .230 .872 .102 .225 .066 
Difficulty paying attention to things .762 .396 .056 .125 .054 .219  .169 .267 .799 .156 .290 .129 
Difficulty remembering what he/she read. .831 .260 .190 .006 .132 .016  .179 .244 .800 .116 .191 .132 
Perceived Physical Appearance              
Feeling that he/she is not good looking .163 .279 .440 -.183 -.229 .574  .306 .099 .511 .160 -.180 .605 
Not liking other people to see his/her scars .074 -.124 -.015 .220 .254 .799  .104 .040 .084 .102 .279 .845 
Being embarrassed about others seeing his/her body .116 .012 .203 .018 .054 .894  .162 .116 .234 .083 .185 .851 
Communication              
Difficulty telling the doctors and nurses how he/she feels .598 .069 .238 .459 .162 -.098  .180 .251 .440 .139 .706 .259 
Difficulty asking the doctors and nurses questions .655 -.117 .051 .519 .046 -.020  .215 .072 .417 .122 .748 .205 
Difficulty explaining his/her illness to other people .539 -.049 -.101 .461 .211 .244  .225 .171 .402 .060 .768 .159 
% of  total variance (initial Eigenvalue) 37% 12% 9% 7% 6% 5%   51% 11% 9% 5% 4% 4% 
a Item factor loadings from Principal Components Analysis with Varimax Rotation and an Eigenvalue cut-off at 1.0
b Varni et al. determined the eight domains through interviews and focus groups
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Table 9 AYA Modified PedsQL Generic Core Scales and Cancer Module correlations between AYA (above the leading diagonal), between
proxies (below the diagonal), and AYA-proxy concurrence on the diagonal
Adolescent and young adult (AYA)




N PA TA W CP A Com
Proxy Total score 0.811 0.918 0.954 0.751 0.788 0.869 0.72 0.709 0.302 0.318 0.581 0.586 0.252* 0.514
Physical health 0.884 0.852 0.755 0.531 0.663 0.716 0.669 0.626 0.213* ns 0.461 0.376 ns 0.362
Psychosocial health 0.951 0.695 0.738 0.835 0.796 0.891 0.68 0.694 0.337 0.404 0.608 0.682 0.33 0.573
Emotional functioning 0.818 0.542 0.897 0.563 0.544 0.576 0.537 0.476 0.373 0.448 0.602 0.492 0.478 0.415
Social functioning 0.85 0.677 0.858 0.651 0.617 0.589 0.537 0.521 ns ns 0.493 0.417 ns 0.438
Study/work functioning 0.888 0.664 0.925 0.724 0.726 0.809 0.633 0.72 0.336 0.346 0.461 0.744 ns 0.573
Pain and hurt 0.801 0.724 0.751 0.681 0.608 0.713 0.541 0.534 ns ns 0.442 0.382 ns 0.486
Nausea 0.682 0.546 0.686 0.569 0.591 0.677 0.661 0.668 0.465 0.345 0.513 0.51 ns 0.37
Procedural anxiety 0.387 ns 0.478 0.506 0.276* 0.460 0.304 0.602 0.591 0.616 0.525 0.411 0.294 0.294
Treatment anxiety 0.489 0.282* 0.564 0.611 0.397 0.481 0.405 0.607 0.752 0.482 0.601 0.478 0.321 0.391
Worry 0.577 0.419 0.609 0.715 0.389 0.494 0.526 0.576 0.633 0.743 0.359 0.351 0.421 0.302
Cognitive problems 0.664 0.372 0.773 0.661 0.622 0.772 0.463 0.525 0.468 0.502 0.461 0.646 0.262* 0.652
Perceived physical
appearance
0.463 0.295 0.515 0.491 0.400 0.477 0.307 0.332 0.427 0.436 0.415 0.541 0.643 0.225*
Communication 0.481 0.226* 0.590 0.522 0.463 0.580 0.404 0.44 0.435 0.517 0.421 0.731 0.509 0.601
Pearson’s correlation coefficients
All correlations were significant at the 0.01 level (two-tailed) unless indicated with an asterisk *
Interpretation: r C 0.5 large effect, 0.3 B r \ 0.5 medium effect, 0.1 B r \ 0.3 small effect [29]
Not significant = ns. AYA sample n = 88; Proxy n = 79
Bolded numbers indicate: Total score versus Cancer Module for both AYA versus AYA and proxy versus proxy; and AYA-proxy concurrence on
the leading diagonal
Fig. 1 a Mean differences in
the AYA modified PedsQL
Generic Core Scales between
adolescent and young adult
(AYA) self-report and proxy-
report (AYA minus proxy*)
with 95% confidence intervals.
*Positive differences indicate
proxies tended to underestimate
AYA HRQOL. b Mean
differences in the AYA
modified PedsQL Cancer
Module between adolescent and
young adult (AYA) self-report
and proxy-report (AYA minus
proxy*) with 95% confidence
intervals. *Positive differences
indicate proxies tended to
underestimate AYA HRQOL,
while negative differences
indicate proxies tended to
overestimate AYA HRQOL
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domains, while the Cancer Module showed a significant
difference in three domains only (nausea, treatment anx-
iety and worry) [17] between on and off-treatment for
more than 12 months.
The high Cronbach alpha values we report for the
Generic Core Total Score (both self and proxy-report);
make it suitable as a summary score of HRQOL outcome
for use in clinical research [28]. For the Generic Core
Scales, our AYA data demonstrated greater internal con-
sistency than that reported by Varni et al. (0.70–0.92).
The factor structures in our data for both the Generic
Core Scales and the Cancer Module Scales were gener-
ally consistent with those reported previously for the
adolescent forms [14–16, 20]. Varni et al. determined the
eight domains of the Cancer Module through interviews
and focus groups [14]. While our AYA data suggests a
better fit with a seven-factor solution (combining worry
and treatment anxiety) and our proxy data suggest a six-
factor solution (combining treatment with procedural
anxiety, and pain and hurt with nausea), we recommend
scoring the AYA PedQL instruments according to Var-
ni’s standard scoring algorithm, as for other PedQL
forms, to enable comparison across age groups and
studies.
The patterns of correlations we found between the
Generic Core Scales and Cancer Module Scales are con-
sistent with the conceptualizations of disease-specific
symptoms as causal indicators of HRQOL [3]. Despite the
high statistical correlation, these domains are conceptually
distinct, and as such provide useful insights in to the impact
of symptoms on HRQOL and function. For example, the
high correlations for the pain and nausea scales (Cancer
Module) with all domains of the Generic Core highlight the
impact pain has on other aspects of HRQOL.
The moderate to strong correlations between self-report
and proxy-report is consistent with current literature [3,
14]. Although patient self-report is the standard for mea-
suring HRQOL, the proxy’s perception, particularly in the
younger 16–19 age-group, may be an influential factor in
health care utilisation, and must be used if the patient is
unable or unwilling to complete the HRQOL assessment.
Potential bias must also be considered. Reassuringly, our
results show that there was little systematical bias in the
proxy reports, although proxies did slightly underestimate
the social and emotional functioning of AYA. Document-
ing the size and direction of this bias informs future use of
proxy ratings on these scales where AYA data are not
available, for whatever reason.
At the time of the study’s commencement, the adoles-
cent forms of these instruments were considered by our
research team (a group of 24 medical specialists, nurses,
psychologists, and researchers working with AYA at the
three recruitment hospitals and collaborating universities)
to be the most appropriate generic and cancer-specific
HRQOL measurement tools for modification for the AYA
target group, because they included role functioning items
appropriate to this age range, they had previously been
shown to be feasible, reliable, and valid in paediatric
populations, and they were brief.
The validation and testing of these new AYA forms
reported here has some limitations. Each dyad was assessed
at only one time point, so the test–retest reliability and
responsiveness were not determined. Information on non-
participants was limited so we could not fully assess the
generalisability of our results. The data are Australian, but
are likely to generalise culturally similar countries such as
New Zealand, the United Kingdom, USA, Canada and
Europe. Wider field-testing of these forms would be
valuable.
For some participants, much time may have passed since
they were diagnosed with their illness and completed
treatment. However, we did not record date of diagnosis.
This may not be a limitation, because although two-thirds
of our AYA sample were off-treatment, almost half of
those people were still experiencing moderate to severe
symptoms. Further, over half of our sample (51/88 = 58%)
reported moderate or severe symptoms, and a quarter of the
people with severe symptoms were off-treatment at
recruitment. This suggests that, from the patient’s per-
spective, symptomatology may be more relevant than
whether the patient is on or off-treatment.
This paper focuses on the provision of appropriate
instruments for the collection of valid outcomes data for
AYA people with cancer and blood disorders—a small
but vital part in the quest for better health outcomes in
this population. These new AYA forms of the PedsQL
Generic Core Scales and the PedsQL Cancer Module
have demonstrated the required reliability and validity for
use as outcome measures in clinical trials, clinical prac-
tice, and future health research into AYAs. We note that
they remain under the copyright of Professor James
Varni’s instruments (held by the MAPI Research Insti-
tute, France), and require author permission to use and
may have licensing costs attached. We recommend that
they be used in conjunction with valid measures of sexual
health and fertility issues which are of concern to this age
group.
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